Why is GSK stock up 1.7% today?

Why is GSK stock up 1.7% today?
GSK rises 1.72% today to GBX1948

GSK plc (GSK) advanced 1.72% after reporting strong Q3 earnings growth and reaffirming its 2026 guidance, capturing renewed buying interest. The move is supported by the stock sustaining prices above its 20-day and 50-day moving averages, but limited by overhead resistance near the 200-day moving average at GBX1,954.

GSK price prediction
24H 0.28%
GBX 1,948
48H 0.26%
GBX 1,947.5
7D 0.76%
GBX 1,957.25
1M 2.63%
GBX 1,993.5
3M 7%
GBX 2,078.52
6M 23.1%
GBX 2,391.18
12M 5.34%
GBX 2,046.18
Current price: GBX 1,942.5 27.50 1.44%
Real-time Data 14:28
Daily range 1919.00 Arrow from to Icon 1934.50
Weekly range 1876.50 Arrow from to Icon 1944.00
Loading...

Highlights

  • GSK delivered 5% sales growth in the third quarter, with year-to-date operating cash flow up £1.1 billion to £7.4 billion.
  • The company raised free cash flow by £1.8 billion and declared a third-quarter dividend of 17 pence per share, reaffirming 2026 guidance.
  • Shares of GSK trade with strong short- and medium-term bullish momentum, with a projected 5-day range of GBX1,914 to GBX1,981 and high probability of further gains if resistance at GBX1,954 is surpassed.

Operating cash flow and dividend grow as 2026 guidance holds

GSK reported strong third-quarter earnings, highlighted by 5% sales growth and robust cash generation. Year-to-date operating cash flow reached £7.4 billion, £1.1 billion above the prior year, while free cash flow increased by £1.8 billion. The company also declared a third-quarter dividend of 17 pence per share and reaffirmed its 2026 guidance, with management addressing segment pressures and pipeline development.

Anton Kharitonov, expert at Traders Union, sees GSK's positive Q3 earnings and cash flow as a temporary boost amid ongoing sector pressures. He notes that technical momentum is fragile, with the price capped below the 200-day moving average at GBX1,954. The neutral oscillator readings reveal a lack of conviction for a sustained rally. Kharitonov is wary of management's ability to address pipeline risks despite the 2026 guidance. "I remain cautious on GSK, as upside potential looks limited and downside may resurface if support levels break."
Viktoras Karapetjanc, expert at Traders Union, believes GSK’s improving cash flow and reaffirmed 2026 outlook reinforce its long-term strategy. He highlights resilient sales growth and a steady dividend as core supports, signaling persistent institutional confidence. The bullish structure remains intact above key moving averages. "With strong financials and management's reiterated vision, I see further growth potential as GSK targets GBX1,981 in the coming sessions."
Sholanke Dele, market strategist, takes a defensive stance given GSK’s failure to clear the 200-day moving average. He notes that neutral momentum signals and macro headwinds could limit further price appreciation. The recent earnings beat does not outweigh broader risks for him. "Caution is warranted here — I see scope for sideways or even weaker action unless buying conviction strengthens."
GlaxoSmithKline asset chart
GlaxoSmithKline price dynamics. Source: TradingView.

Bullish signals persist with price capped below key moving average

GSK is trading above its 20-day and 50-day moving averages at GBX1,878 and GBX1,846, indicating continued bullish momentum in the short and medium term. The price remains just below the 200-day moving average at GBX1,954, which serves as the main resistance level, with immediate support at the week high of GBX1,944. Momentum indicators are positive, with the MACD and Awesome Oscillator both signaling ongoing buying interest, and the Average Directional Index (ADX) pointing to a neutral trend. All three oscillators—Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI)—are in neutral ranges. Bull/Bear Power (BBP) is positive, supporting the dominance of buyers in recent trading.

Earlier, analysts noted that GSK's technical setup and improving cash flow positioned the stock for possible movement if it could surpass key resistance. The current price action reinforces this scenario, with a decisive close above GBX1,954 now serving as the primary level to watch for confirmation of further upside potential.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.